search
Back to results

Bioavailability Study of Isotretinoin Capsules 40 mg Under Fed Condition

Primary Purpose

Healthy

Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Isotretinoin
Sponsored by
Dr. Reddy's Laboratories Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy adult human male volunteers between 18 to 45 years of age (both inclusive) living in and around Ahmedabad city or western part of India.
  • Having a Body Mass Index (BMI) between 18.5-27.5 (both inclusive), calculated as weight in kg / height in meter2.
  • Not having any significant disease in medical history or clinically significant abnormal findings during screening, medical history, physical examination,laboratory evaluations, 12- lead ECG and X-ray chest recordings.
  • Able to understand and comply with the study procedures, in the opinion of the principal investigator.
  • Able to comply to use 2 forms of effective contraception methods simultaneously during Isotretinoin study, and for 1 month after study.
  • Able to give voluntary written informed consent for participation in the trial.
  • Able to read and/or understand drug medication Guide either in English or in a provided translation when given along with informed consent form.

Exclusion Criteria

  • Known hypersensitivity or idiosyncratic reaction to Isotretinoin or any of the excipients including parabens or any related drug.
  • History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
  • Ingestion of any medicine including herbal medicines at any time within 14 days before dosing in Period I. In any such case subject selection will be at the discretion of the Principal Investigator.
  • Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria.
  • Use of any recreational drugs or history of drug addiction or testing positive in prestudy drug scans.
  • A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum,whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to receiving study medicine.
  • Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study.
  • The presence of clinically significant abnormal laboratory values during screening.
  • History or presence of psychiatric disorders.
  • A history of difficulty in donating blood.
  • Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study.

Sites / Locations

  • Lambda Therapeutic Research Ltd.,

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Isotretinoin capsules, 40 mg

AMNESTEEM

Arm Description

Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd

AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc

Outcomes

Primary Outcome Measures

Area under curve (AUC)

Secondary Outcome Measures

Full Information

First Posted
June 25, 2013
Last Updated
June 25, 2013
Sponsor
Dr. Reddy's Laboratories Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT01888224
Brief Title
Bioavailability Study of Isotretinoin Capsules 40 mg Under Fed Condition
Official Title
Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With Amnesteem Capsules 40 mg of Mylan Pharmaceuticals Inc., in Healthy, Adult, Male Human Subjects Under Fed Conditions.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2011
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
July 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. Reddy's Laboratories Limited

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To characterise the pharmacokinetic profile of sponsor's test formulation Isotretinoin Capsules 40 mg in comparison to the reference formulation Amnesteem (Containing Isotretinoin) Capsules 40 mg after single oral dose administration to healthy, normal, adult, human male subjects under fed condition.
Detailed Description
An open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, oral bioequivalence study of Isotretinoin Capsules 40 mg under fed conditions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Isotretinoin capsules, 40 mg
Arm Type
Experimental
Arm Description
Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
Arm Title
AMNESTEEM
Arm Type
Active Comparator
Arm Description
AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc
Intervention Type
Drug
Intervention Name(s)
Isotretinoin
Other Intervention Name(s)
AMNESTEEM
Intervention Description
Isotretinoin Capsules,40 mg
Primary Outcome Measure Information:
Title
Area under curve (AUC)
Time Frame
Pre-dose (0) and 0.5, 1,1.5,2,2.5,3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8,10,12,16,20,24, 36, 48,72 and 96 hrs

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy adult human male volunteers between 18 to 45 years of age (both inclusive) living in and around Ahmedabad city or western part of India. Having a Body Mass Index (BMI) between 18.5-27.5 (both inclusive), calculated as weight in kg / height in meter2. Not having any significant disease in medical history or clinically significant abnormal findings during screening, medical history, physical examination,laboratory evaluations, 12- lead ECG and X-ray chest recordings. Able to understand and comply with the study procedures, in the opinion of the principal investigator. Able to comply to use 2 forms of effective contraception methods simultaneously during Isotretinoin study, and for 1 month after study. Able to give voluntary written informed consent for participation in the trial. Able to read and/or understand drug medication Guide either in English or in a provided translation when given along with informed consent form. Exclusion Criteria Known hypersensitivity or idiosyncratic reaction to Isotretinoin or any of the excipients including parabens or any related drug. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system. Ingestion of any medicine including herbal medicines at any time within 14 days before dosing in Period I. In any such case subject selection will be at the discretion of the Principal Investigator. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria. Use of any recreational drugs or history of drug addiction or testing positive in prestudy drug scans. A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum,whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to receiving study medicine. Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study. The presence of clinically significant abnormal laboratory values during screening. History or presence of psychiatric disorders. A history of difficulty in donating blood. Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. Alpeshkumar Patel, MD
Organizational Affiliation
Lambda Therapeutic Research Limited
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lambda Therapeutic Research Ltd.,
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380 061
Country
India

12. IPD Sharing Statement

Learn more about this trial

Bioavailability Study of Isotretinoin Capsules 40 mg Under Fed Condition

We'll reach out to this number within 24 hrs